Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

BACKGROUND: We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials. METHODS: Patients ⩾18 years received oral sunitinib 50 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Gore, M E, Szczylik, C, Porta, C, Bracarda, S, Bjarnason, G A, Oudard, S, Lee, S-H, Haanen, J, Castellano, D, Vrdoljak, E, Schöffski, P, Mainwaring, P, Hawkins, R E, Crinò, L, Kim, T M, Carteni, G, Eberhardt, W E E, Zhang, K, Fly, K, Matczak, E, Lechuga, M J, Hariharan, S, Bukowski, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647545/
https://www.ncbi.nlm.nih.gov/pubmed/26086878
http://dx.doi.org/10.1038/bjc.2015.196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647545/
https://www.ncbi.nlm.nih.gov/pubmed/26086878
http://dx.doi.org/10.1038/bjc.2015.196

Ejemplares similares